Trajan Wealth LLC Purchases New Position in Kenvue Inc. $KVUE

Trajan Wealth LLC acquired a new position in Kenvue Inc. (NYSE:KVUE) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 476,912 shares of the company’s stock, valued at approximately $9,114,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership bought a new stake in shares of Kenvue in the 2nd quarter worth $6,528,000. Jump Financial LLC raised its stake in shares of Kenvue by 210.6% in the second quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock worth $1,147,000 after purchasing an additional 37,170 shares during the last quarter. AXA S.A. lifted its holdings in shares of Kenvue by 21.1% during the second quarter. AXA S.A. now owns 48,892 shares of the company’s stock valued at $1,023,000 after purchasing an additional 8,524 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Kenvue by 219.1% during the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock valued at $2,040,000 after purchasing an additional 66,930 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Kenvue by 0.6% during the second quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock valued at $39,217,000 after buying an additional 10,885 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $19.41 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. Kenvue Inc. has a one year low of $14.02 and a one year high of $21.63. The firm has a market capitalization of $37.27 billion, a P/E ratio of 22.30, a PEG ratio of 1.36 and a beta of 0.47. The business has a fifty day moving average of $19.08 and a 200 day moving average of $18.21.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.29 EPS. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 4.3%. The ex-dividend date of this dividend is Wednesday, August 12th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is currently 96.55%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of recent analyst reports. UBS Group decreased their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Barclays lifted their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat, Kenvue has an average rating of “Hold” and an average price target of $19.27.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.